ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,384,847, issued on Aug. 12, was assigned to Dragonfly Therapeutics Inc. (Waltham, Mass.).
"Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen" was invented by Gregory P. Chang (Medford, Mass.), Ann F. Cheung (Lincoln, Mass.), Asya Grinberg (Lexington, Mass.), Eva Gutierrez (Waltham, Mass.), William Haney (Wayland, Mass.), Nicolai Wagtmann (Concord, Mass.), Bradley M. Lunde (Lebanon, N.H.) and BIanka Prinz (Lebanon, N.H.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated anti...